Cytokinetics Shares Fall on Heart Trial Results
Cytokinetics reported late-stage trial data showing its drug aficamten improved symptoms for heart patients. However, shares fell six percent as analysts questioned the treatments modest benefits and safety risks.
Xurve View
Insights:
Xurve View